Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?
- PMID: 36560985
- PMCID: PMC9764894
- DOI: 10.4103/aian.aian_668_22
Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?
References
-
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:1581–7. - PubMed
-
- Guidelines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e440–1. - PubMed
-
- Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41:1229–45. - PubMed
-
- Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke:Meta-analysis of 5 randomized trials. Stroke. 2019;50:2156–62. - PubMed
